BioCardia (BCDA) Cost of Revenue (2016 - 2020)

BioCardia (BCDA) has reported Cost of Revenue for 5 consecutive years, with $4000.0 the latest figure, recorded in Q1 2020.

• On a quarterly basis, Cost of Revenue fell 96.23% year-over-year to $4000.0 in Q1 2020; TTM through Dec 2020 was $4000.0, a 98.88% decrease from a year earlier, with the FY2020 full-year figure at $4000.0, down 98.88% from the prior year.
• Cost of Revenue was $4000.0 for Q1 2020 at BioCardia, down from $37000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $226000.0 in Q1 2016 and troughed at $4000.0 in Q1 2020.
• A 5-year average of $136176.5 and a median of $156000.0 in 2016 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 41.48% in 2019 and plunged 96.23% in 2020, its largest moves.
• Over 5 years, Cost of Revenue stood at $168000.0 in 2016, then decreased by 1.79% to $165000.0 in 2017, then retreated by 29.7% to $116000.0 in 2018, then slumped by 68.1% to $37000.0 in 2019, then plunged by 89.19% to $4000.0 in 2020.
• The last three Cost of Revenue figures came in at $4000.0 (Q1 2020), $37000.0 (Q4 2019), and $24000.0 (Q3 2019), per Business Quant data.